Editor's Note: Green and red arrows refer to intraday stock price movement.NEW YORK ( TheStreet) -- CHANGE IN RATINGS Bridgepoint Education ( BPI) upgraded at Piper from Neutral to Overweight. $31 price target. Valuation appears artificially depressed and regulatory clarity is pending. Boston Scientific ( BSX - Get Report) upgraded at Goldman to Neutral. Estimates have likely bottomed out. $7 price target. Chubb ( CB) upgraded at Janney from Neutral to Buy. The property/casualty market is improving. Career Education ( CECO - Get Report) upgraded at Piper from Underweight to Neutral, Piper Jaffray said. $25 price target. Company has a strong balance sheet and generates healthy cash flow. Con-way ( CNW) upgraded at BofA/Merrill from Neutral to Buy, Bank of America/Merrill Lynch said. $45 price target. Estimates also increased, to match the company's new guidance. Diamond Foods ( DMND) upgraded at BofA/Merrill from Neutral to Buy, Bank of America/Merrill Lynch said. $85 price target. Estimates also boosted, as the Pringles purchase will add to earnings. Frontline ( FRO - Get Report) downgraded at Sterne to Neutral. Company could face a more prolonged recovery in the tanker market. Halliburton ( HAL - Get Report) upgraded at Morgan Stanley from Equal-weight to Overweight, Morgan Stanley said. $85 price target. Company is leveraged to a solid oil cycle. Juniper Networks ( JNPR - Get Report) downgraded at Auriga from Buy to Hold. $40 price target. Switching business could be hurt by competition. Knight Transportation ( KNX) downgraded at BofA/Merrill to Neutral from Buy. $19 price target. Company is facing slower growth. Netlogic Microsystems ( NETL) downgraded at Auriga from Buy to Hold. $36 price target. Company is facing challenges in multiple areas. RSC Holdings ( RRR) upgraded at Goldman to Buy. Company is in the early stages of a pricing upcycle. Sapient ( SAPE) downgraded at Goldman from Buy to Neutral, Goldman Sachs said. Valuation call, based on a $15 price target. Trius Therapeutics ( TSRX) initiated at BofA/Merrill with a Buy rating and $11 price target. Torezolid offers many potential advantages for MRSA, Bank of America/Merrill Lynch said. End of report.
More from Stocks
Boeing, FedEx, Federal Reserve, WeWork, General Motors - 5 Things You Must Know
U.S. stock futures decline slightly and oil prices slip following one of the biggest single-day price jumps on record; investors adopt a cautious stance ahead of the Federal Reserve's two-day rate-setting meeting and the start of formal U.S.-China trade talks; FedEx, Adobe and Chewy report earnings.
Dow Futures Drift Lower, Crude Pares Gains As Markets Gear for Fed Rate Decision
Global stocks edged lower again Tuesday, following one of the biggest single-day declines in oil prices on record, as investors adopted a cautious stance on risk ahead of the Federal Reserve's two-day rate-setting meeting and the start of formal U.S.-China trade talks later this week.
Boeing Boosts China Forecast; Report Says FAA Faces Rebuke For 737 MAX Approval
Boeing shares were indicated modestly lower in pre-market trading Tuesday after the world's biggest planemaker lifted its forecast for aircraft demand in China, the world's biggest market, amid ongoing questions over the return of its troubled 737 MAX jet.
Shopify Falls 5% in After-Hours Trading on Secondary Offering Plan
Company to offer 1.9 million Class A subordinate voting shares.